TNF-a-stimulated cell adhesion molecule CD62E and CD106 and monocyte
adhesion when administered in HBMECs and HUVECs (Lee and Lee 2008). It also
decreases the interaction among the ECs and monocyte via stimulation of PPARs
that decrease monocyte adhesion in culture cells and animals. Genistein blocks the
LPS-stimulated release of MCP-1 from macrophages that activated in reduced
migration of monocyte in-vitro (Nagarajan et al. 2008). It blocks the LPS-mediated
countenance of NTP and iNOS in vascular tissue that blocks vascular changes and
hypotension. It exerts a potential effect on neurodegenerative diseases, diabetes
mellites (DM), metabolic syndromes, rheumatoid arthritis (RA) and chronic colitis
by modulating inflammatory response (Jantan et al. 2015). Genistein modulated the
Th1-dominant immune reaction by rising IL-4 secretion and inhibit the release of
IFN-c in a collagen-mediated rheumatoid arthritis rat (Wang et al. 2008).
Nonalcoholic fatty liver disease (NAFLD) is an obesity-related fatty liver disease
initiated by PINFLCs and TNF-a and leads to rising fatty acid uptake and the
defunctions of hepatic cells. It decreases the high fat diet-stimulated hepatic
steatosis by enhancing liver performance and reducing the level of plasma TNF-a
count in rats (Yalniz et al. 2007). Furthermore, genistein decreased LPS-induced
DP uptake loss in rat MNGCs by reducing the release of NO, TNF-a and microglia
stimulation this might prevent the pathogenesis of Parkinson’s disease produced by
dopaminergic neuron damage. The growth of astrocytes at Ab accumulation sites is
the early neuropathological change that initiates inflammation in Alzheimer’s disease (AD). The NOD, LRR- and pyrin domain-containing protein 3 (NLRP3)
inflammasome reported being associated with inflammatory bowel disease
including colitis due to its potential ability to induce IL-1b secretion. Genistein
blocks NLRP3 inflammasome via TGR5-cAMP signaling in macrophages and it
can be a possibly effective therapeutic drug for inflammatory bowel diseases (Chen
et al. 2019).
6.2.2 Classification of Immunomodulators
Several factors play a deciding role in determining the efficacy of an
immunomodulatory compound such as its mechanism of action structural conformation, molecular weight, and solubility Table 6.2.
6.2.2.1 Based on the Mechanism of Action
See Table 6.2.
220
V. K. Gurjar and D. Pal
adhesion when administered in HBMECs and HUVECs (Lee and Lee 2008). It also
decreases the interaction among the ECs and monocyte via stimulation of PPARs
that decrease monocyte adhesion in culture cells and animals. Genistein blocks the
LPS-stimulated release of MCP-1 from macrophages that activated in reduced
migration of monocyte in-vitro (Nagarajan et al. 2008). It blocks the LPS-mediated
countenance of NTP and iNOS in vascular tissue that blocks vascular changes and
hypotension. It exerts a potential effect on neurodegenerative diseases, diabetes
mellites (DM), metabolic syndromes, rheumatoid arthritis (RA) and chronic colitis
by modulating inflammatory response (Jantan et al. 2015). Genistein modulated the
Th1-dominant immune reaction by rising IL-4 secretion and inhibit the release of
IFN-c in a collagen-mediated rheumatoid arthritis rat (Wang et al. 2008).
Nonalcoholic fatty liver disease (NAFLD) is an obesity-related fatty liver disease
initiated by PINFLCs and TNF-a and leads to rising fatty acid uptake and the
defunctions of hepatic cells. It decreases the high fat diet-stimulated hepatic
steatosis by enhancing liver performance and reducing the level of plasma TNF-a
count in rats (Yalniz et al. 2007). Furthermore, genistein decreased LPS-induced
DP uptake loss in rat MNGCs by reducing the release of NO, TNF-a and microglia
stimulation this might prevent the pathogenesis of Parkinson’s disease produced by
dopaminergic neuron damage. The growth of astrocytes at Ab accumulation sites is
the early neuropathological change that initiates inflammation in Alzheimer’s disease (AD). The NOD, LRR- and pyrin domain-containing protein 3 (NLRP3)
inflammasome reported being associated with inflammatory bowel disease
including colitis due to its potential ability to induce IL-1b secretion. Genistein
blocks NLRP3 inflammasome via TGR5-cAMP signaling in macrophages and it
can be a possibly effective therapeutic drug for inflammatory bowel diseases (Chen
et al. 2019).
6.2.2 Classification of Immunomodulators
Several factors play a deciding role in determining the efficacy of an
immunomodulatory compound such as its mechanism of action structural conformation, molecular weight, and solubility Table 6.2.
6.2.2.1 Based on the Mechanism of Action
See Table 6.2.
220
V. K. Gurjar and D. Pal